Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

Circulation

Volumn 102, Issue 4, 2000, Pages 411-418

  Williamson, D James ^a,b   Wallman, Lucinda L ^a   Jones, Richard ^d   Keogh, Anne M ^a   Scroope, Frances ^c   Penny, Ronald ^a   Weber, Cornelia ^d   Macdonald, Peter S ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c Roche Products Pty Ltd   (Australia)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Endothelin; Hypertension, pulmonary; Scleroderma; Trials

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATRIAL NATRIURETIC FACTOR; BOSENTAN; DILTIAZEM; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; FUROSEMIDE; GLYCERYL TRINITRATE; ISOSORBIDE; LISINOPRIL; NIFEDIPINE; NITRIC OXIDE; NORADRENALIN; PLACEBO; SPIRONOLACTONE; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INDEX; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG RESISTANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SYSTEMIC VASCULAR RESISTANCE;

EID: 0034713874     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.4.411     Document Type: Article

References (39)

1. Rubin L. Primary pulmonary hypertension. N Engl J Med. 1997;336: 111-117.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
3. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986; 29:515-524.
4. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580-587.
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
6. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol), and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993;70:366-370.
7. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409-415.
8. Barst RJ, Rubin LJ, Long WAM, et al, for the Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-302.
9. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996; 124:820-824.
10. Hoeper MM, Wilke T, Welte T, et al. How effective is the treatment with high dose nifedipine for primary pulmonary hypertension? Semin Respir Crit Care Med. 1994;15:490-494.
11. Bando K, Armitage JM, Paradis IL, et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg. 1994;108:1056-1065.
12. Sarris GE, Smith JA, Shumway NE, et al. Long-term results of combined heart-lung transplantation: the Stanford experience. J Heart Lung Transplant. 1994;13:940-949.
13. Wagenwoort CA, Mooi WJ. Biopsy pathology of the pulmonary vasculature. In: Gottlieb LS, Neville AM, Walker F, eds. Biopsy Pathology Series. London, UK: Chapman and Hall Medical: 1989:241-245.
14. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Human Pathol. 1990;21:467-474.
15. Pepke-Zaba J, Higenbottam TW, Dinh Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
16. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995;151:384-389.
17. Williamson JP, Hay ward C, Rogers P, et al. Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation. 1996;94:477-482.
18. Maguire JJ, Davenport AP. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995;115:191-197.
19. Li H, Chen S-J, Chen Y-F, et al. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol. 1994;77: 1451-1459.
20. Chen S-J, Chen Y-F, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol. 1995;79:2122-2131.
21. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464-469.
22. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
23. Clozel M, Breu V, Burri K, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759-761.
24. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270:228-235.
25. Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996;60:124-137.
26. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995; 346:732-736.
27. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
28. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumarol. 1988;15: 202-205.
29. Lipkin DP, Scriven AJ, Crake T, et al. Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J. 1986;292: 653-655.
30. Löffler B-M, Maire J-P. Radioimmunological determination of endothelin peptides in human plasma: a methodological approach. Endothelium. 1994;1:273-286.
31. De la Mata J, Gomez-Sanchez M, Aranzana M, et al. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum. 1994;37:1528-1533.
32. Haynes WG, Ferro CJ, O'Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860-1870.
33. Löffler B-M, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the non peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett. 1993;333:108-110.
34. Adnot S, Chabrier PE, Andrivet P, et al. Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension. Am Rev Respir Dis. 1987;136:951-956.
35. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-1585.
36. Adnot S, Andrivet P, Chabrier PE, et al. Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension: physiological correlates and response to peptide infusion. J Clin Invest. 1989; 83:986-993.
37. Rich R, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987;76:135-141.
38. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med. 1990;112:485-491.
39. Miller O, Tang S, Keech A, et al. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet. 1995;346:51-52.